BlackRock’s Forte Biosciences FBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $26M | Buy |
1,222,862
+1,156,941
| +1,755% | +$27.4M | ﹤0.01% | 3098 |
|
|
2026
Q1 | $1.71M | Buy |
65,921
+1,425
| +2% | +$41.1K | ﹤0.01% | 4168 |
|
|
2025
Q4 | $1.76M | Buy |
64,496
+13,834
| +27% | +$243K | ﹤0.01% | 4151 |
|
|
2025
Q3 | $760K | Buy |
50,662
+16,967
| +50% | +$195K | ﹤0.01% | 4370 |
|
|
2025
Q2 | $436K | Buy |
33,695
+26,892
| +395% | +$231K | ﹤0.01% | 4482 |
|
|
2025
Q1 | $52.8K | Hold |
6,803
| – | – | ﹤0.01% | 4915 |
|
|
2024
Q4 | $154K | Hold |
6,803
| – | – | ﹤0.01% | 4676 |
|
|
2024
Q3 | $38K | Sell |
6,803
-191
| -3% | -$1.97K | ﹤0.01% | 4864 |
|
|
2024
Q2 | $93.9K | Hold |
6,994
| – | – | ﹤0.01% | 4721 |
|
|
2024
Q1 | $122K | Sell |
6,994
-299
| -4% | -$5.22K | ﹤0.01% | 4689 |
|
|
2023
Q4 | $150K | Buy |
7,293
+6
| +0.1% | +$84 | ﹤0.01% | 4709 |
|
|
2023
Q3 | $121K | Sell |
7,287
-6
| -0.1% | -$133 | ﹤0.01% | 4800 |
|
|
2023
Q2 | $190K | Sell |
7,293
-363
| -5% | -$9.43K | ﹤0.01% | 4752 |
|
|
2023
Q1 | $193K | Sell |
7,656
-819
| -10% | -$20.6K | ﹤0.01% | 4786 |
|
|
2022
Q4 | $212K | Sell |
8,475
-7
| -0.1% | -$179 | ﹤0.01% | 4838 |
|
|
2022
Q3 | $226K | Sell |
8,482
-80
| -0.9% | -$2.54K | ﹤0.01% | 4946 |
|
|
2022
Q2 | $278K | Sell |
8,562
-23,679
| -73% | -$752K | ﹤0.01% | 4947 |
|
|
2022
Q1 | $1.18M | Sell |
32,241
-442
| -1% | -$16.7K | ﹤0.01% | 4611 |
|
|
2021
Q4 | $1.75M | Buy |
32,683
+1,814
| +6% | +$122K | ﹤0.01% | 4464 |
|
|
2021
Q3 | $2.28M | Sell |
30,869
-136
| -0.4% | -$75.3K | ﹤0.01% | 4266 |
|
|
2021
Q2 | $26.1M | Buy |
31,005
+20,538
| +196% | +$18.5M | ﹤0.01% | 3139 |
|
|
2021
Q1 | $8.97M | Buy |
10,467
+4,417
| +73% | +$3.62M | ﹤0.01% | 3637 |
|
|
2020
Q4 | $5.51M | Buy |
6,050
+1,843
| +44% | +$1.73M | ﹤0.01% | 3664 |
|
|
2020
Q3 | $5.1M | Buy |
4,207
+2,229
| +113% | +$1.48M | ﹤0.01% | 3567 |
|
|
2020
Q2 | $721K | Sell |
1,978
-2,475
| -56% | -$1.11M | ﹤0.01% | 4132 |
|
|
2020
Q1 | $2.04M | Sell |
4,453
-68
| -2% | -$26.6K | ﹤0.01% | 3649 |
|
|
2019
Q4 | $903K | Buy |
4,521
+228
| +5% | +$51.7K | ﹤0.01% | 4026 |
|
|
2019
Q3 | $1.07M | Sell |
4,293
-166
| -4% | -$252K | ﹤0.01% | 3955 |
|
|
2019
Q2 | $11.2M | Buy |
4,459
+30
| +0.7% | +$89K | ﹤0.01% | 3183 |
|
|
2019
Q1 | $18.1M | Buy |
4,429
+425
| +11% | +$1.64M | ﹤0.01% | 2791 |
|
|
2018
Q4 | $12.3M | Buy |
4,004
+235
| +6% | +$1.01M | ﹤0.01% | 2975 |
|
|
2018
Q3 | $22M | Buy |
3,769
+759
| +25% | +$2.89M | ﹤0.01% | 2816 |
|
|
2018
Q2 | $10.5M | Buy |
3,010
+166
| +6% | +$608K | ﹤0.01% | 3212 |
|
|
2018
Q1 | $12.6M | Sell |
2,844
-7
| -0.2% | -$32.4K | ﹤0.01% | 3007 |
|
|
2017
Q4 | $11M | Buy |
2,851
+761
| +36% | +$3.04M | ﹤0.01% | 3100 |
|
|
2017
Q3 | $9.77M | Buy |
2,090
+24
| +1% | +$107K | ﹤0.01% | 3181 |
|
|
2017
Q2 | $9.32M | Buy |
+2,066
| New | +$11.6M | ﹤0.01% | 3210 |
|
Other funds holding FBRX
AAA
VCM
WP
IHAM
CS
BlackRock's FBRX Position: Q2 2026 in Review
BlackRock increased its Forte Biosciences (FBRX) stake by 1,755% in Q2 2026, buying an estimated $27.4M and bringing the position to 1,222,862 shares worth $26M. The position accounts for ﹤0.01% of the portfolio, ranked #3098.
BlackRock first reported a position in FBRX in Q2 2017 and has held it in 37 quarters since. The position peaked at $26.1M in Q2 2021. 56 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.
- BlackRock held 1,222,862 shares of Forte Biosciences worth $26M as of Q2 2026.
- BlackRock bought 1,156,941 Forte Biosciences shares in Q2 2026, an estimated $27.4M.
- Forte Biosciences made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3098 holding.
- BlackRock first reported a position in Forte Biosciences in Q2 2017 and has held it in 37 quarters since.
- BlackRock's Forte Biosciences position peaked at $26.1M in Q2 2021.
- 56 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.